2013
Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)
Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, Ostacher M, Thase ME, Nierenberg A. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). The Pharmacogenomics Journal 2013, 14: 182-191. PMID: 23670706, DOI: 10.1038/tpj.2013.16.Peer-Reviewed Original ResearchConceptsPeripheral bloodTreatment responseLithium Treatment Moderate-Dose Use StudyLi respondersClinical responseTreatment initiationTreatment respondersMood symptomsLithium respondersEarly markerBipolar disorderRespondersBloodPatientsGene expression differencesSpecific roleSubjectsResponseBiochemical levelSymptomsDifferencesMonths
2012
Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation
Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A, Lorberg B, Mane S, Zhao H, Sinha R, Bhagwagar Z, Beech R. Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biology Of Mood & Anxiety Disorders 2012, 2: 15. PMID: 22967286, PMCID: PMC3448519, DOI: 10.1186/2045-5380-2-15.Peer-Reviewed Original ResearchBCL2-antagonist/killer 1Insulin receptor substrate 2Pathway analysisBCL2 gene family membersGene family membersRegulation of apoptosisGene expression profilesPro-apoptotic genesAnti-apoptotic genesClinical responseBipolar disorderBlood gene expression profilesLevel of expressionMolecular basisTranscript probesExpression profilesGeneGo MetaCore softwareMetaCore softwarePeripheral blood gene expression profilesCell deathSubstrate 2GenesOpen-label treatmentGold standard medicationDifferential response